Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.52 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501013 | 0.92 | PDK1 (0.59) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL1866437 | 0.89 | HSP90AA1 (0.53) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL1866153 | 0.89 | HSP90AA1 (0.61) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL500601 | 0.89 | HSP90AA1 (0.51) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL1862943 | 0.88 | HSP90AA1 (0.52) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL501392 | 0.88 | HSP90AA1 (0.50) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL5002925 | 0.88 | PDK1 (0.52) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL1865421 | 0.87 | HSP90AA1 (0.53) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL1865169 | 0.87 | HSP90AA1 (0.51) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL15380652 | 0.87 | HSP90AA1 (0.49) | PDK1HSP90AA1HSP90B1TRAP1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937094-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-20 | — | — | US | claimed |
| US-20130303493-A1 | Triazole Compounds that Modulate HSP90 Activity | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | US | claimed |
| EP-2323737-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corp. (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2010017545-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARAMCEUTICALS CORP. (US) | 2010-02-11 | — | — | WO | claimed |
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200316090-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2020-10-08 | — | — | US | disclosed |
| US-10722525-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10675360-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10232049-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-9956293-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956293-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-8106083-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106083-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2323737-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corp. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
| WO-2010017545-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARAMCEUTICALS CORP. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017545-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARAMCEUTICALS CORP. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316090-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | PDK1 2418/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | PDK1 2418/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | PDK1 1289/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-10675360-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | PDK1 2418/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-10232049-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | PDK1 2418/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-20130303493-A1 | Triazole Compounds that Modulate HSP90 Activity | HSP90AB1, HSP90B1, HSP90AA1 | PDK1 1289/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-10722525-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | PDK1 2418/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | PDK1 2418/4885HSP90AA1 5/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.